STEMLINE THERAPEUTICS INC
STML evidence brief
What we can confirm
- BioSniper Score:
- 9.9 / 10
- Lead Asset:
- elzonris (Approved)
What it means
What to watch
Prepared research question
What matters most for STML—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Tracking 6 pipeline candidates · 9 clinical trials · 2 FDA decisions for STEMLINE THERAPEUTICS INC.
Run STEMLINE THERAPEUTICS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available STEMLINE THERAPEUTICS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
6 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Governance
Frequently asked questions
What is STEMLINE THERAPEUTICS INC's lead drug candidate?
STEMLINE THERAPEUTICS INC's most advanced tracked candidate is elzonris (Approved) for blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Who is the CEO of STEMLINE THERAPEUTICS INC?
Ivan Bergstein is the chief executive officer of STEMLINE THERAPEUTICS INC (STML).
What therapeutic areas does STEMLINE THERAPEUTICS INC focus on?
STEMLINE THERAPEUTICS INC develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.